En
Register Log in
  1. Main
  2. Conference
  3. Fundamental and applied research for key propriety...
  4. Autoantibodies and Cytokines in the Pathogenesis o...

Autoantibodies and Cytokines in the Pathogenesis of Systemic Sclerosis: From Molecular Mechanisms to Clinical Therapy

Proceeding
All-Russian scientific conference with International Participation «Fundamental and applied research for key propriety areas of bioecology and biotechnology»
Creative commons logo
Published in:
All-Russian scientific conference with International Participation «Fundamental and applied research for key propriety areas of bioecology and biotechnology»
Authors:
Iuliia A. Kudrova 1 , Sofia V. Erzukova 1
Work direction:
Биохимия. Биомедицинские технологии
Pages:
85-90
Received: 16 May 2025

Rating:
Article accesses:
90
Published in:
Информрегистр РИНЦ
1 Chuvash State University
For citation:
Kudrova I. A., & Erzukova S. V. (2025). Autoantibodies and Cytokines in the Pathogenesis of Systemic Sclerosis: From Molecular Mechanisms to Clinical Therapy. Fundamental and applied research for key propriety areas of bioecology and biotechnology, 85-90. Чебоксары: PH "Sreda".

Abstract

Systemic sclerosis (SSc) is a rare connective tissue disorder characterized by vasculopathy, abnormal immune system activation with autoantibody production, and fibrosis development. This article reviews current therapeutic approaches for SSc, including the use of methotrexate, tofacitinib, and ziritaxestat. It discusses the role of interleukin-17 (IL-17) in disease pathogenesis and the potential of brodalumab, an IL-17 inhibitor, in reducing the modified Rodnan skin score (mRSS) and skin thickness. The study aims to systematically analyze the pathogenesis, clinical manifestations, and dermatological changes associated with SSc. Conclusions: Investigating the role of autoantibodies and cytokines in the pathogenesis of systemic sclerosis reveals the molecular mechanisms underlying fibrosis and chronic inflammation. Understanding these processes enables the development of therapeutic strategies, including the suppression of pro-inflammatory cytokines and blockade of autoantibodies.

References

  1. 1. Allanore Y., Simms R., Distler O. [et al.]. Systemic sclerosis // Nat Rev Dis Primers. 2015. Vol. 1. Article 15002. DOI: 10.1038/nrdp.2015.2. EDN YYBTZB
  2. 2. Denton C.P., Khanna D. Systemic sclerosis // Lancet. 2017. Vol. 390. No. 10103. Pp. 1685–1699. DOI: 10.1016/S0140-6736(17)30933-9. EDN YEVPGE
  3. 3. Di Maggio G., Confalonieri P., Salton F. [et al.]. Biomarkers in Systemic Sclerosis: An Overview // Curr Issues Mol Biol. 2023. Vol. 45. No. 10. Pp. 7775–7802. DOI: 10.3390/cimb45100490. EDN EUATCX
  4. 4. Ефремов М.И. Прогноз фармакологической активности гваянолида артабсина / М.И. Ефремов, Е.Н. Шамитова, Н.Е. Гималдинова // Донецкие чтения 2023: образование, наука, инновации, культура и вызовы современности: материалы VIII Международной научной конференции (Донецк, 25–27 октября 2023 года). – Донецк: Донецкий государственный университет, 2023. – С. 220–222. – EDN GLPNVJ.
  5. 5. Журавлева Н.В. Трудности диагностики системной склеродермии / Н.В. Журавлева, Е.Н. Шамитова, Н.А. Комелягина // Современная кардиология и вопросы междисциплинарного взаимодействия: материалы Республиканской научно-практической конференции (Чебоксары, 23 мая 2018 года) / под ред. Е.И. Бусалаевой. – Чебоксары: Чувашский государственный университет имени И.Н. Ульянова, 2018. – С. 154–158. – EDN UQWTJS.

Comments(0)

When adding a comment stipulate:
  • the relevance of the published material;
  • general estimation (originality and relevance of the topic, completeness, depth, comprehensiveness of topic disclosure, consistency, coherence, evidence, structural ordering, nature and the accuracy of the examples, illustrative material, the credibility of the conclusions;
  • disadvantages, shortcomings;
  • questions and wishes to author.